Bahija Jallal is Chief Executive Officer and Director of the Board of Immunocore, the leading T-Cell Receptor (TCR) biotechnology company.
Prior to Immunocore, Jallal was President of MedImmune, Astra Zeneca’s global biologics research and development unit. She was also Executive Vice President of AstraZeneca and a member of its senior executive team.
Jallal has authored over 70 peer-reviewed publications and has more than 15 patents. She is a Council Member of the Government-University-Industry Research Roundtable of the National Academies of Sciences, Engineering and Medicine.
Jallal serves on the Board of Trustees of Johns Hopkins University and Medicine.
Jallal received a Master’s degree in Biology from the Universite de Paris VII in France, and her Doctorate in Physiology from the University of Pierre & Marie Curie in Paris. She conducted her postdoctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany.
